N/A N=406 National Cardiogenic Shock Initiative
Cardiogenic Shock · Acute Myocardial Infarction · STEMI - ST Elevation Myocardial Infarction
Primary: Number of Participants Who Survived at Discharge — 287 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Cardiogenic Shock Intravascular Cooling Trial
Cardiogenic Shock
Primary: Number of Participants With Episodes of Arrhythmia — 0; 1 Participants — p=1
N/A N=47 Synchronized Cardiac Assist for Cardiogenic Shock
Shock, Cardiogenic · High Risk Percutaneous Coronary Interventions
Primary: Number of Participants With Device and Procedure Related Serious Adverse Events — 11; 5 Participants
Phase 4 N=129 Non Invasive Mechanical Ventilation in Acute Cardiogenic Pulmonary Edema
Acute Cardiogenic Pulmonary Edema
Primary: Number of Patients Who Were Intubated — 5; 4; 10 participants
Phase 2 N=50 Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
Cardiac Arrest
Primary: Time to Shock Reversal — 55; 49 hours
N/A N=141 Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock
Cardiac Arrest
Primary: Survival Rate - Number of Participants Alive — 55; 20; 32; 34 Participants — p=<0.001
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=142 Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
Shock · Cardiovascular Diseases · Critical Illness
Primary: Perfused Vessel Denisty (PVD) — 22.8; 23.8; 20.2; 22.5 mm/mm^2
Phase 1 N=20 Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study
Septic Shock
Primary: Standing Dose of Norepinephrine Which is Required to Maintain a Mean Arterial Pressure (MAP) of 65 mmHg - Hour 1 — 7.4; 27.6 mcg/min
N/A N=32 CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass
Heart Failure
Primary: Survival — 20 Participants
Phase 2 N=7 Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia
Septic Shock
Primary: Organ-failure-free Days — 26 units on a scale
Phase 3 N=188 Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
N/A N=677 Unexpected Cardiac Arrest in Intensive Care Unit
Heart Arrest
Primary: Number of Patients With Unexpected Cardiac Arrest — 677; 30,722 Participants
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
N/A N=44 Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
Circulatory Shock · Cardiovascular Shock
Primary: Perfused Vessel Density (PVD) — 24.81; 20.44; 26.41; 21.88 mm/mm^2
N/A N=51 NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock
SIRS · Sepsis · Shock
Primary: Pattern of NT-proBNP, Biomarkers and Surface Markers on Leukocytes — 902; 4,429 pg/ml
Phase 1 N=14 Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
N/A N=15 Clinical Hemodynamic Study of Balloon Counterpulsation in Advanced Heart Failure
Heart Failure
Primary: Impact of Intra-aortic Balloon Pump Activation on Left Ventricular Stroke Work. — 939; 5628; 667; NA mmHg-mL
N/A N=114 Non-invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema
Cardiogenic Pulmonary Oedema
Primary: Need for an Endotracheal Intubation Within Seven Days After Onset of Cardiopulmonary Edema at the Intensive Care Unit — 5; 5 Participants — p=1.000
Phase 3 N=110 A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Edema, Cardiac
Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001
N/A N=180 GDT by Cardiac Index Trending Via a Radial Arterial Line in General Surgery
Reduction of Length of Hospitality Stay, Reduction of Perioperative Complications
Primary: Postoperative Complications — 52; 72 numbers of complications
Phase 2 N=101 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Traumatic Shock
Primary: Number of Blood Products Transfused — 1.7; 3.0 Litre
N/A N=15 ECPR for Refractory Out-Of-Hospital Cardiac Arrest
Cardiac Arrest · Heart Arrest · Sudden Cardiac Arrest
Primary: Emergency Department Arrivals Under 30 Minutes — 5 Participants
Phase 1 N=30 Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)
Ischemic Cardiomyopathy
Primary: Safety of Autologous-bone-marrow Injections — 1; 1; 0; 1 participants
Phase 3 N=882 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass Grafting · Mitral Valve Surgery · Low Cardiac Output Syndrome
Primary: Number of Dual Efficacy Endpoint Events — 56; 48 events
Phase 1 N=24 Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)
Safety and Tolerability · Healthy Volunteers
Primary: Safety and Tolerability — 7; 8; 12; 3 AEs
Phase 2 N=37 PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)
Non-ischemic Dilated Cardiomyopathy
Primary: Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs) — 1; 0; 0; 1 Participants
Phase 4 N=314 Effects of Microplegia on Transfusion Rates After Cardiac Surgery
Aortic Valve Disease · Mitral Valve Disease
Primary: Intraoperative and Postoperative Transfusions — 2.43; 2.97; 4.42; 3.50 units of blood per participant — p=0.354
N/A N=164 Extracardiac Complications After Cardiac Surgery
Acute Lung Injury · Sepsis · Infections
Primary: Acute Lung Injury After Cardiac Surgery — 20 participants — p=<0.05
N/A N=25 CentriMag RVAS U.S. Post-approval Study Protocol
Right Ventricular Failure
Primary: Survival — 80 percentage of survival at 30 days